Charles Ferté - Concepedia

Author

Charles Ferté

Also Known As

C Ferté, C. Ferte, C. Fertè, C. Ferté, C. H. J. de la Ferte, CHARLES FERTE, Charles Ferte, Charles Ferté, Karine Bouhier-Leporrier

242

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris-Saclay Université Paris-Sud Centre National de la Recherche Scientifique

About

Charles Ferté is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	2.3K
2	Health Sciences	9	9	442
3	Cell Biology	2	2	22
4	Public Health	1	1	37
5	Biostatistics	1	1	14

Charles Ferté

Publications

Citations

H-Index

Page 1

	Year	Citations
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou, The Lancet Oncology Tumor ImmunologyCancer ImmunosurveillanceOncologic ImagingMedicineImmunology	2018	1.2K
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 Stéphane Champiat, Laurent Dercle, Samy Ammari, Clinical Cancer Research	2016	1.2K
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial Christophe Massard, Stefan Michiels, Charles Ferté, Cancer Discovery	2017	747
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy Roberto Ferrara, Laura Mezquita, Matthieu Texier, JAMA Oncology	2018	719
Exomics and immunogenics Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay, OncoImmunology Tumor ImmunologyCancer ImmunosurveillanceMedicineMutational HeterogeneityPathogenesis	2014	187
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Clinical Cancer Research	2013	172
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial Loïc Verlingue, David Malka, Adrien Allorant, European Journal of Cancer Effective StrategySurgical OncologyGliomaMedicinePrecision Medicine	2017	163
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial Cécile Jovelet, Ecaterina Ileana, Marie‐Cécile Le Deley, Clinical Cancer Research	2016	111
The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features Elaine Johanna Limkin, Sylvain Reuzé, Alexandre Carré, Scientific Reports	2019	105
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status Dan Ou, Pierre Blanchard, Silvia Rosellini, Oral Oncology Adaptive RadiotherapyAdvanced HeadRadiomics SignatureRadiation TherapyMedicine	2017	98

Page 1